STAT

Opinion: As global markets for generic drugs fail, poor people pay the price

In some countries, suspicion about the quality of unfamiliar "no-name" pills prompts residents to choose brand-name drugs, usually at premium prices.
A pharmacist searches for drugs in a pharmacy in Lagos, Nigeria. Source: PIUS UTOMI EKPEI/AFP/Getty Images

Healthy competition from generic drugs is often held up as a “cure” for high drug prices — a shared concern across rich and developing countries alike. For many low- and middle-income countries, however, a new report from the Center for Global Development that we co-authored shows that global markets for generic medicines are failing, leaving the poorest patients without safe and affordable essential medicines.

The first point of failure is drug quality. In wealthy countries, residents can usually trust that all drugs on pharmacy shelves are safe, authentic, and potent. Most

You're reading a preview, sign up to read more.

More from STAT

STAT2 min read
This Troubled Biotech Needed Cash, So It Turned To A Predatory Lender: Its Own CEO
I don’t write about Northwest Biotherapeutics much anymore because it’s not cool to punch down. However, there was a juicy nugget in the cancer biotech’s recently filed 10-Q that had to be shared. It’s another example of a biotech executive getting r
STAT2 min read
Top Scientist Categorically Denies Any Wrongdoing In Novartis Data Manipulation Scandal
The Novartis scientist who was ousted by the drug maker in connection with a scandal over data manipulation broke his silence.
STAT4 min readSociety
Opinion: Virtual And Augmented Reality Can Save Lives By Improving Surgeons’ Training
Rapid advances in the development of medical devices in the 21st century are contributing to healthier lives, but bring with them a new challenge: teaching clinicians how to use these often-complicated technologies. Teaching them poorly, or failing t